A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
ConditionHealthy Volunteers
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorArcus Biosciences, Inc.
About this trial
The purpose of this study is assess the safety and tolerability of AB102 and characterize the pharmacokinetics (PK) profile of AB102 after single and multiple ascending oral dose(s).
Eligibility criteria
Qualifiers
Understands the study procedures in the Informed Consent Form and is willing and able to comply with the protocol.
BMI: 19.0 to 30.0 kg/m2, inclusive, at screening.
All prescribed medication must have been stopped at least 30 days prior to admission to the clinical site. An exception is made for hormonal contraceptives that may be used throughout the study.
Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG, vital signs, and complete neurological examination, as judged by the Investigator.
Disqualifiers
Have a history of relevant atopy, drug hypersensitivity and/or food allergies.
Using tobacco products within 3 months prior to the screening.
Have a significant infection or known inflammatory process on screening or admission.
Have received any vaccination within 14 days of admission date for non-live vaccines or 28 days of admission date for live attenuated vaccines.
Trial design
Treatments tested in this trial
- AB102
- Placebo
Treatment groups
130 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov